

Controlled Release of Bioactive Transforming Growth Factor Beta 1 from Affinity Peptide Hydrogels

Joshua McCall,¹ Chien-Chi Lin^{1,2} & Kristi Anseth^{1,2}

¹Dept. of Chemical & Biological Engineering and ²Howard Hughes Medical Institute, University of Colorado, Boulder, CO USA

Statement of Purpose: Transforming growth factor beta 1 (TGF β ₁) is a potent chemokine implicated in numerous cellular functions, including growth and differentiation of human mesenchymal stem cells (hMSCs). Biomaterial platforms capable of releasing this growth factor in a controllable manner present a powerful tool for dictating stem cell fate. In this work, we utilize a thiol-acrylate photopolymerization scheme to covalently incorporate affinity binding peptide sequences Trp-Ser-His-Trp (WSHW)¹ and Lys-Arg-Ile-Trp-Phe-Ile-Pro-Arg-Ser-Ser-Trp-Tyr (KRIWFIPRSSWY)², into poly(ethylene glycol) (PEG) diacrylate hydrogel networks. The objective of this work is to tune the release of bioactive TGF β ₁ from these materials in order to control hMSC differentiation.

Methods: *Synthesis and Purification of Affinity Peptides:* Peptides were synthesized with a solid-phase peptide synthesizer and purified using reverse phase HPLC. Purified peptides were identified with MALDI-TOF mass spectrometry. *Preparation of Affinity Hydrogels:* Macromer solutions of PEG diacrylate (PEG_{DA}-10kDa) at a concentration of 20 mM and TGF β ₁ (Peprotech) at a concentration of 25 nM were prepared with varying concentration of affinity peptides, including (CGGGGWSHW) and (CKRIWFIPRSSWY), along with 1 mM photoinitiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP)³. Solutions were exposed to 365 nm UV light at an intensity of \sim 10 mW/cm² for 3 min. *Release of TGF β ₁:* Hydrogels were placed in 1.5 mL PBS release buffer at 4°C, and the buffer was collected at predetermined time points. Diffusion was assumed to be 1-D and with “sink” conditions. TGF β ₁ concentration in the release supernatant was determined with an ELISA kit (BD Biosciences). *Bioactivity of Released TGF β ₁:* Mink lung epithelial cells permanently transfected with a SMAD reported gene (PE-25 cells) were plated at a density of \sim 50,000 cells/cm² in 24-well plates. Affinity hydrogels were placed in transwell plates, and cells were incubated 20 hours in serum-free high-glucose DMEM (Gibco). The cell lysate was mixed with luciferase




Figure 1. a) TGF β ₁ released as a function of percent loaded for the two affinity peptide sequences (WSHW) and (KRIWFIPRSSWY) over a 26-day time period, **b)** materials exhibit different initial rate of TGF β ₁ release.

substrate and luminescence was measured with spectrophotometry.

Results: Affinity hydrogels containing binding peptides WSHW or KRIWFIPRSSWY, at a molar ratio of 1000 to TGF β ₁ (R=1000), showed unique release profiles over a 26-day timescale (Figure 1a). The total amount of TGF β ₁ released from the gels is due to different K_D values for the affinity interaction between respective peptide and TGF β ₁. Comparison of initial release rate (Figure 1b) shows different effective diffusivities for the two peptide-functionalized hydrogels. This further confirms affinity-controlled diffusion from the polymer matrix. Furthermore, the bioactivity of released growth factor was confirmed with a PE-25 reporter cell assay. Hydrogels with affinity peptides (R=1000) showed luminescence approximately two-fold higher than that of gels without TGF β ₁, similar to the response from gels with equivalent amounts of entrapped TGF β ₁ (Figure 2).




Figure 2. TGF β ₁ released from affinity gels shows a similar fold-increase in relative luminescence from PE-25 cells, compared to gels made with entrapped TGF β ₁.

Conclusions: A biomaterial platform utilizing a thiol-acrylate photopolymerization reaction scheme to incorporate WSHW or KRIWFIPRSSWY affinity peptide sequences into PEG hydrogels was developed to control the release of TGF β ₁. PE-25 cell studies confirm that TGF β ₁ bioactivity is maintained post-release. Tailorable release of TGF β ₁ from affinity hydrogels is in development for controlling the differentiation of encapsulated mesenchymal stem cells.

References:¹Young, G, et. al., Jour Biol Chem. 2004; 279:46:47633-47642, ²Dotor, J, et. al., Cytokine. 2007;39:106-115, ³Fairbanks, B, et. al., Biomaterials. 2009;30:6702-7, ⁶The authors would like to thank our funding sources: NIH (1R01DE12998), and Howard Hughes Medical Institute.